Clearmind Medicine Inc. (CMND)

Nasdaq: CMND · Pharmaceutical Preparations · Vancouver, British Columbia, CA · filing with the SEC since 2021

Grade4.7

◀ Past 4.4● Present 3.6▶ Future 5.9

Overview Business Financials Grade Forecast Sentiment Ownership People Filings Patents Chart

Income statement, as filed

In US dollars (USD), as filed; per-share figures in US dollars; share counts. The fiscal year ends in October.

Income statement, by fiscal year, newest first
Fiscal year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period ending	Oct 31, 2025	Oct 31, 2024	Oct 31, 2023	Oct 31, 2022	Oct 31, 2021
Report filed	Jan 20, 2026	Jan 22, 2025	Jan 29, 2024	Feb 6, 2023	·
Research and development	2,056,525	1,382,808	1,544,229	3,080,991	473,652
Selling, general and administrative	·	4,362,117	4,759,205	3,170,440	2,219,745
General and administrative	3,610,652	4,362,117	4,759,205	3,170,440	2,219,745
Total operating expenses	5,667,177	5,744,925	6,303,434	6,251,431	2,693,397
Finance costs	3,857	5,386	·	·	·
Net finance income (costs)	1,880,639	868,213	-2,316,586	-613,578	-24,564
Income before income taxes	-3,786,538	-4,876,712	-8,603,465	-6,865,009	-2,725,288
Income tax expense	70,445	377,966	17,372	29,859	·
Net income	-3,856,983	-5,254,678	-8,620,837	-6,894,868	-2,725,288
Earnings per share, basic	-30.35	-67.80^r	-1,703.04^r	-6,364.40^b	-3,526.40^b
Earnings per share, diluted	-30.35	-67.80^r	-1,703.04^r	-6,364.40^b	-3,526.40^b
Weighted average shares, basic	127,093	77,503^r	5,062^r	1,083^rb	773^rb
Weighted average shares, diluted	127,093	77,503^r	5,062^r	1,083^rb	773^rb

As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.Share counts and per-share figures are on the newest report's basis, after the 1-for-40 reverse split.A dot is a line not tagged for that period. ^r restated by the company in a later report; ^b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.

What each line is, and the XBRL concept behind it

Research and development spent on inventing what it sells nextifrs-full:ResearchAndDevelopmentExpense

Selling, general and administrative the cost of selling and of running the companyifrs-full:SellingGeneralAndAdministrativeExpense

General and administrative the cost of running the company itselfifrs-full:GeneralAndAdministrativeExpense

Total operating expenses the running costs togetherifrs-full:OperatingExpense

Finance costs what its borrowing costifrs-full:InterestExpense

Net finance income (costs) interest earned less interest paid, outside the businessifrs-full:FinanceIncomeCost

Income before income taxes profit before taxifrs-full:ProfitLossBeforeTax

Income tax expense tax charged on the period's profitifrs-full:IncomeTaxExpenseContinuingOperations

Net income the whole group's profit, minority holders' share includedifrs-full:ProfitLoss

Earnings per share, basic net income per share outstandingifrs-full:BasicEarningsLossPerShare

Earnings per share, diluted net income per share, counting every share that could be issuedifrs-full:DilutedEarningsLossPerShare

Weighted average shares, basic the average count of shares outstandingifrs-full:WeightedAverageShares

Weighted average shares, diluted the average count with every share that could be issuedifrs-full:AdjustedWeightedAverageShares

SI Assistanton CMND · research, not advice